Afamelanotide: FDA-Approved Melanocyte Peptide

While melanotan 2 exists in a regulatory gray zone, its close relative afamelanotide carries full FDA approval — making it one of the few melanocortin peptides with an established clinical profile. Marketed as Scenesse by Clinuvel Pharmaceuticals, afamelanotide received FDA approval in 2019 for erythropoietic protoporphyria (EPP), a painful and disabling genetic disease. Its approval story illuminates both the potential and the challenges of melanocortin therapeutics.

What Is Afamelanotide?

Afamelanotide is a synthetic alpha-MSH analog with a single amino acid substitution — norleucine replaces methionine at position 4 — that dramatically increases potency and metabolic stability compared to native alpha-MSH. It is delivered as a biodegradable implant (a solid rod approximately 1.7 cm long) inserted subcutaneously. The implant releases afamelanotide over approximately 60 days.

This slow-release delivery method maintains stable plasma levels, avoiding the peaks and troughs of injection protocols that drive side effects, and eliminates the need for frequent self-injection.

Erythropoietic Protoporphyria: The Approved Indication

EPP is a rare genetic disorder caused by deficient ferrochelatase enzyme activity, causing accumulation of protoporphyrin IX in red blood cells. When protoporphyrin-laden red blood cells reach skin capillaries and are exposed to visible light (particularly wavelengths around 408 nm), they absorb light energy, generating reactive oxygen species that cause intense burning pain, swelling, and — in severe cases — tissue damage.

Patients with EPP describe the pain as burning from the inside, triggered by even minutes of sunlight exposure. Many are effectively housebound or severely restricted in outdoor activities. Conventional sunscreens do not protect against the wavelengths that cause EPP phototoxicity.

Afamelanotide addresses EPP by stimulating melanin production throughout the skin. The resulting increased melanin density absorbs the problematic visible light wavelengths before they reach the protoporphyrin in dermal blood vessels, preventing the phototoxic reaction. Clinical trials showed afamelanotide significantly increased the time EPP patients could spend in sunlight without pain — from minutes to hours — dramatically improving quality of life.

Clinical Trial Results

The pivotal Phase III trial published in JAMA Dermatology randomized EPP patients to afamelanotide implants or placebo every 60 days. The afamelanotide group showed significant increases in direct sun exposure time without pain, reduced pain episodes, and dramatically improved quality of life scores. The improvement was consistent across multiple dosing cycles.

European approval preceded US FDA approval, with Clinuvel having marketed Scenesse in Europe since 2014. The FDA approval in 2019 was based on this accumulated European experience plus additional US trial data.

Comparison to Melanotan 2

Afamelanotide and melanotan 2 are both potent MC1R agonists that stimulate melanogenesis. The key differences are:

Selectivity: Afamelanotide shows somewhat greater MC1R selectivity than MT-2, reducing off-target effects on MC3R/MC4R (appetite, libido) — though these effects are not completely absent with afamelanotide.

Delivery: Afamelanotide uses a slow-release implant providing stable levels over 60 days. MT-2 requires daily or frequent injections.

Regulatory status: Afamelanotide is FDA-approved for EPP; MT-2 is not approved for any indication.

Clinical evidence: Afamelanotide has robust Phase III trial data; MT-2 has primarily Phase I/II data.

Expanded Research

Beyond EPP, Clinuvel is investigating afamelanotide for vitiligo (where it may promote repigmentation by stimulating residual melanocytes), solar urticaria, and variegate porphyria. Early data in vitiligo are promising, with afamelanotide combined with narrowband UVB producing faster repigmentation than UVB alone.

Research into photoprotection for xeroderma pigmentosum (a rare DNA repair disorder with extreme sun sensitivity) and as a protective agent for outdoor workers is ongoing.

FAQ

Can afamelanotide be used for cosmetic tanning? Not legally. It is approved only for EPP and must be administered by a physician. Off-label use for tanning exists but represents unauthorized use of a prescription drug.

What does the afamelanotide implant feel like? The implant is inserted with a sterile applicator under local anesthesia, typically in the abdominal area. It is palpable as a small nodule. Insertion site reactions (bruising, mild pain) resolve within days. The implant is not removed — it dissolves over approximately 60 days.

Does afamelanotide have the same side effects as melanotan 2? Similar but generally milder due to the slow-release delivery. Nausea and flushing occur in some patients, particularly after initial implants, but tend to diminish with subsequent treatments.

Track your supplements in Optimize.